Home › Encyclopedia › Buserelin: Uses, Evidence, and Research Status
Approved

Buserelin: Uses, Evidence, and Research Status

Molecular formulaC60H86N16O13
Molecular weight1239.4 g/mol
Registered trials43
PubChem CID50225

What buserelin is

Buserelin is a synthetic peptide related to gonadotropin releasing hormone (GnRH). It is registered under PubChem CID 50225, with a molecular formula of C60H86N16O13. No structured label indications, mechanism text, or brand name data were available for this summary, so specific FDA-approved uses and mechanism details are not presented here.

What the evidence shows

Buserelin has been studied across 43 registered clinical trials. Among the sampled studies, one phase 4 trial examined the duration of GnRH-analogue downregulation and pregnancy rates, though it was terminated. Another phase 4 trial compared age versus ovarian reserve markers as a basis for therapy in IVF and ICSI cycles, which was also terminated. A phase 1/phase 2 study looked at replacing fresh embryo transfers with frozen embryo transfers using vitrification; its status is listed as unknown.

These trials point to a research focus in assisted reproduction and fertility treatment contexts, though the terminated and unknown statuses mean firm conclusions cannot be drawn from this sample alone.

Reported side effects

No FAERS adverse event report data were available for buserelin in this dataset, so a side effect summary cannot be provided here.

FAQ

What is buserelin used for?
Detailed approved-use information was not available in this dataset. Clinical trial data indicate research interest in fertility treatment contexts such as IVF and ICSI cycles.
How many clinical trials have studied buserelin?
There are 43 registered clinical trials involving buserelin. A sample of these includes phase 4 studies on downregulation timing and ovarian reserve based therapy, as well as an earlier phase study on embryo transfer methods.
Were the sampled buserelin trials successful?
Two of the sampled phase 4 trials were terminated, and a phase 1/phase 2 trial has an unknown status. This means the sample alone does not establish clear outcomes.
What side effects are associated with buserelin?
No adverse event report data were available in this dataset, so a summary of reported side effects cannot be given here.
What is the chemical identity of buserelin?
Buserelin is a peptide compound with the molecular formula C60H86N16O13, cataloged under PubChem CID 50225.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 50225 ClinicalTrials.gov (NCT00436319, NCT00823121, NCT01816789)

Updated 2026-08-15